BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37031291)

  • 1. Oncolytic adenoviruses and the treatment of pancreatic cancer: a review of clinical trials.
    Taylor IP; Lopez JA
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):8117-8129. PubMed ID: 37031291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in oncolytic adenovirus therapy for pancreatic cancer.
    Nattress CB; Halldén G
    Cancer Lett; 2018 Oct; 434():56-69. PubMed ID: 29981812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical evaluation of the gorilla-derived HAdV-B AdV-lumc007 oncolytic adenovirus 'GoraVir' for the treatment of pancreatic ductal adenocarcinoma.
    Bots STF; Harryvan TJ; Groeneveldt C; Kinderman P; Kemp V; van Montfoort N; Hoeben RC
    Mol Oncol; 2024 May; 18(5):1245-1258. PubMed ID: 38037840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-derived pancreatic tumour organoids identify therapeutic responses to oncolytic adenoviruses.
    Raimondi G; Mato-Berciano A; Pascual-Sabater S; Rovira-Rigau M; Cuatrecasas M; Fondevila C; Sánchez-Cabús S; Begthel H; Boj SF; Clevers H; Fillat C
    EBioMedicine; 2020 Jun; 56():102786. PubMed ID: 32460166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Bromodomain Proteins Enhances Oncolytic HAdVC5 Replication and Efficacy in Pancreatic Ductal Adenocarcinoma (PDAC) Models.
    Miao T; Symonds A; Hickman OJ; Wu D; Wang P; Lemoine N; Wang Y; Linardopoulos S; Halldén G
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Present Status of Immuno-Oncolytic Viruses in the Treatment of Pancreatic Cancer.
    Haller SD; Monaco ML; Essani K
    Viruses; 2020 Nov; 12(11):. PubMed ID: 33213031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma.
    Murphy AM; Besmer DM; Moerdyk-Schauwecker M; Moestl N; Ornelles DA; Mukherjee P; Grdzelishvili VZ
    J Virol; 2012 Mar; 86(6):3073-87. PubMed ID: 22238308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic Adenovirus Expressing ST13 Increases Antitumor Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Against Pancreatic Ductal Adenocarcinoma.
    Zhang Y; Ye M; Huang F; Wang S; Wang H; Mou X; Wang Y
    Hum Gene Ther; 2020 Aug; 31(15-16):891-903. PubMed ID: 32475172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic virotherapy for pancreatic ductal adenocarcinoma: A glimmer of hope after years of disappointment?
    Tassone E; Muscolini M; van Montfoort N; Hiscott J
    Cytokine Growth Factor Rev; 2020 Dec; 56():141-148. PubMed ID: 32859494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of a novel, cyclooxygenase-2-targeted, interferon-expressing, conditionally replicative adenovirus for pancreatic cancer therapy.
    Armstrong L; Arrington A; Han J; Gavrikova T; Brown E; Yamamoto M; Vickers SM; Davydova J
    Am J Surg; 2012 Nov; 204(5):741-50. PubMed ID: 22748294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of oncolytic adenoviruses with chemotherapies: an overview and future directions.
    Bressy C; Benihoud K
    Biochem Pharmacol; 2014 Jul; 90(2):97-106. PubMed ID: 24832861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects.
    Bazan-Peregrino M; Garcia-Carbonero R; Laquente B; Álvarez R; Mato-Berciano A; Gimenez-Alejandre M; Morgado S; Rodríguez-García A; Maliandi MV; Riesco MC; Moreno R; Ginestà MM; Perez-Carreras M; Gornals JB; Prados S; Perea S; Capella G; Alemany R; Salazar R; Blasi E; Blasco C; Cascallo M; Hidalgo M
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 35149591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
    Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
    Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivery of improved oncolytic adenoviruses by mesenchymal stromal cells for elimination of tumorigenic pancreatic cancer cells.
    Kaczorowski A; Hammer K; Liu L; Villhauer S; Nwaeburu C; Fan P; Zhao Z; Gladkich J; Groß W; Nettelbeck DM; Herr I
    Oncotarget; 2016 Feb; 7(8):9046-59. PubMed ID: 26824985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study.
    Musher BL; Rowinsky EK; Smaglo BG; Abidi W; Othman M; Patel K; Jawaid S; Jing J; Brisco A; Leen AM; Wu M; Sandin LC; Wenthe J; Eriksson E; Ullenhag GJ; Grilley B; Leja-Jarblad J; Hilsenbeck SG; Brenner MK; Loskog ASI
    Lancet Oncol; 2024 Apr; 25(4):488-500. PubMed ID: 38547893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of capsid-modified oncolytic adenoviruses and their combinations with gemcitabine or silica gel on pancreatic cancer.
    Kangasniemi L; Parviainen S; Pisto T; Koskinen M; Jokinen M; Kiviluoto T; Cerullo V; Jalonen H; Koski A; Kangasniemi A; Kanerva A; Pesonen S; Hemminki A
    Int J Cancer; 2012 Jul; 131(1):253-63. PubMed ID: 21834073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer gene therapy with oncolytic adenoviruses.
    Guse K; Hemminki A
    J BUON; 2009 Sep; 14 Suppl 1():S7-15. PubMed ID: 19785073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Development of Oncolytic Adenovirus Therapy in the Past and Future - For the Case of Pancreatic Cancer.
    Sato-Dahlman M; Yamamoto M
    Curr Cancer Drug Targets; 2018; 18(2):153-161. PubMed ID: 28228084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic adenoviruses for the treatment of brain tumors.
    Gomez-Manzano C; Fueyo J
    Curr Opin Mol Ther; 2010 Oct; 12(5):530-7. PubMed ID: 20886384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
    Watanabe K; Luo Y; Da T; Guedan S; Ruella M; Scholler J; Keith B; Young RM; Engels B; Sorsa S; Siurala M; Havunen R; Tähtinen S; Hemminki A; June CH
    JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.